BIOLINERX     Print Page  Close Window

SEC filings
BIOLINERX LTD. filed this Form 424B5 on 07/26/2017
Entire Document

This summary highlights selected information contained elsewhere in this prospectus that we consider important.  This summary does not contain all of the information you should consider before investing in the ADSs and the Warrants.  You should read this summary together with the entire prospectus, including the risks related to our most advanced therapeutic candidates, BL-8040, AGI-134 and BL-5010, our business, our industry, investing in our Ordinary Shares and our location in Israel, that we describe under “Risk Factors,” and our consolidated financial statements and the related notes, which are incorporated by reference herein, before making an investment in the ADSs and the Warrants.
Our Business
We are a clinical stage biopharmaceutical development company dedicated to identifying, in-licensing and developing therapeutic candidates that have advantages over currently available therapies or that address unmet medical needs.  Our current development and commercialization pipeline consists of a clinical-stage therapeutic candidate − BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; a near-clinical candidate – AGI-134, a recently acquired immuno-oncology agent in near-clinical development for solid tumors; and a product that is being commercialized − BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution, which has been launched for sale in Europe as a medical device for the non-surgical removal of benign skin lesions.  In addition, we have five other therapeutic candidates in various stages of clinical and preclinical development.  We generate our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a relatively high probability of therapeutic and commercial success.  To date, except for BL-5010, none of our therapeutic candidates have been approved for marketing or sold commercially. Our strategy includes commercializing our therapeutic candidates throughout-licensing arrangements with biotechnology and pharmaceutical companies.  We also evaluate, on a case-by-case basis, co-development and similar arrangements and the commercialization of our therapeutic candidates independently.
In December 2014, we entered into a strategic collaboration with Novartis Pharma AG, or Novartis, for the co-development of selected Israeli-sourced novel drug candidates.  Under the agreement, we intend, in collaboration with Novartis, to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.  Additionally, in January 2016, we entered into a collaboration with MSD, known as Merck in the United States and Canada, in the field of cancer immunotherapy and, in September 2016, we entered into a collaboration with Genentech, Inc., or Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BL-8040 in combination with Atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications.
Our focus is on the therapeutic areas of oncology and immunology.  However, we may also in-license therapeutic compounds outside of these areas in connection with our strategic collaboration with Novartis, as well as to a limited extent for our independent pipeline as the opportunities arise.
Our Corporate Information
Our principal executive offices are located at 2 HaMaayan Street, Modiin 7177871, Israel, and our telephone number is +972 (8) 642-9100.  Our website is  Information contained in our website is not incorporated by reference into and does not constitute part of this prospectus supplement.
S - 1